CMMI to Test Part D Payment Model & Update to MA VBID Model
FDA Approves Cabozantinib for Previously Treated HCC
U.S. Cancer Death Rate Continues 25-Year Decline, ACS Report Finds
CMS Opens Data Submission Period for MIPS from 1/2 to 4/2
FDA Approves Tagraxofusp-erzs for Blastic Plasmacytoid Dendritic Cell Neoplasm
FDA Approves Calaspargase Pegol-mknl for Pediatric/AYA ALL
FDA Approves Olaparib for Ovarian, Fallopian, Peritoneal Cancers
FDA Approves Pembrolizumab for Merkel Cell Carcinoma
ACCC Statement on Administration's MA & Part D Proposal to Tackle Drug Prices
FDA Approves Trastuzumab-pkrb for Treatment of HER2-Positive Breast Cancer
PTAC Votes to Recommend MASON Model
ACCC Signs Letter Opposing Proposed Medicare Part B IPI Model
FDA Approves Atezolizumab for Metastatic NSq NSCLC
CMS Strengthens Federal Support to Alaska Following Earthquake
ACCC Mourns the Loss of Lee E. Mortenson, DPA, MPA, MS
ACCC to Host 12/5 Webinar on Part B Proposed Changes
FDA Approves Gilteritinib for Acute Myeloid Leukemia
FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusion
CMS Releases Medicare Part C and Part D Proposed Rule
ACCC Signs Letter of Support for CLINICAL TREATMENT Act
FDA Approves Venetoclax for Acute Myeloid Leukemia
FDA Approves Glasdegib for Acute Myeloid Leukemia
ACS Releases Report on Current State of Cancer Screening
"Feel More Like You" Program to Help Cancer Patients with Physical Changes
FDA Approves Brentuximab Vedotin for Peripheral T-Cell Lymphoma
CMS Strengthens Federal Support to Californians Affected by Wildfires
CMS to Host November 19 PFS Final Rule Open Call
ACCC Releases CY 2019 MPFS and OPPS Final Rule Summaries
FDA Approves Pembrolizumab for Hepatocellular Carcinoma
CMS to Unveil Mandatory Medicare Radiation Oncology Payment Model
